MARC details
| 000 -CABECERA |
|---|
| campo de control de longitud fija |
06175cam a2200457Mi 4500 |
| 001 - NÚMERO DE CONTROL |
|---|
| campo de control |
96121 |
| 003 - IDENTIFICADOR DEL NÚMERO DE CONTROL |
|---|
| campo de control |
ES-MaUEC |
| 005 - FECHA Y HORA DE LA ÚLTIMA TRANSACCIÓN |
|---|
| campo de control |
20230102112739.0 |
| 006 - CÓDIGOS DE INFORMACIÓN DE LONGITUD FIJA--CARACTERÍSTICAS DEL MATERIAL ADICIONAL |
|---|
| campo de control de longitud fija |
m o d |
| 007 - CAMPO FIJO DE DESCRIPCIÓN FÍSICA--INFORMACIÓN GENERAL |
|---|
| campo de control de longitud fija |
cr un|---aucuu |
| 008 - DATOS DE LONGITUD FIJA--INFORMACIÓN GENERAL |
|---|
| campo de control de longitud fija |
170603s2017 sz ob 000 0 eng d |
| 020 ## - NÚMERO INTERNACIONAL ESTÁNDAR DEL LIBRO |
|---|
| Número Internacional Estándar del Libro |
3319551078 |
| Información calificativa |
(electronic bk.) |
| 020 ## - NÚMERO INTERNACIONAL ESTÁNDAR DEL LIBRO |
|---|
| Número Internacional Estándar del Libro |
9783319551074 |
| Información calificativa |
(electronic bk.) |
| 020 ## - NÚMERO INTERNACIONAL ESTÁNDAR DEL LIBRO |
|---|
| ISBN cancelado o inválido |
331955106X |
| 020 ## - NÚMERO INTERNACIONAL ESTÁNDAR DEL LIBRO |
|---|
| ISBN cancelado o inválido |
9783319551067 |
| Información calificativa |
(print) |
| 040 ## - FUENTE DE LA CATALOGACIÓN |
|---|
| Centro catalogador/agencia de origen |
EBLCP |
| Centro/agencia transcriptor |
EBLCP |
| Centro/agencia modificador |
GW5XE |
| -- |
N$T |
| -- |
OCLCQ |
| -- |
YDX |
| -- |
AZU |
| -- |
UAB |
| -- |
UPM |
| -- |
OCLCF |
| -- |
COO |
| -- |
OCLCO |
| -- |
IOG |
| -- |
OCLCO |
| -- |
MERER |
| -- |
ESU |
| -- |
OCLCQ |
| -- |
OCLCO |
| -- |
OCLCQ |
| -- |
OCLCO |
| -- |
JG0 |
| -- |
OCLCO |
| -- |
OCLCQ |
| -- |
OCLCA |
| -- |
ES-MaUEC |
| Lengua de catalogación |
spa |
| 050 #4 - SIGNATURA TOPOGRÁFICA DE LA BIBLIOTECA DEL CONGRESO |
|---|
| Número de clasificación |
QH588.S83 |
| Número de documento/Ítem |
2017 EB |
| 100 1# - ENTRADA PRINCIPAL--NOMBRE DE PERSONA |
|---|
| Nombre de persona |
Balistreri, Carmela Rita. |
| 245 10 - MENCIÓN DE TÍTULO |
|---|
| Título |
Endothelial progenitor cells : |
| Resto del título |
a new real hope? |
| Mención de responsabilidad, etc. |
Carmela Rita Balistreri. |
| 264 #1 - PRODUCCIÓN, PUBLICACIÓN, DISTRIBUCIÓN, FABRICACIÓN Y COPYRIGHT |
|---|
| Producción, publicación, distribución, fabricación y copyright |
Cham |
| Nombre del de productor, editor, distribuidor, fabricante |
Springer |
| Fecha de producción, publicación, distribución, fabricación o copyright |
2017. |
| 300 ## - DESCRIPCIÓN FÍSICA |
|---|
| Extensión |
1 recurso en línea (99 páginas) |
| 336 ## - TIPO DE CONTENIDO |
|---|
| Término de tipo de contenido |
Texto |
| Código de tipo de contenido |
txt |
| Fuente |
rdacontent |
| 337 ## - TIPO DE MEDIO |
|---|
| Nombre/término del tipo de medio |
electrónico |
| Código del tipo de medio |
c |
| Fuente |
rdamedia |
| 338 ## - TIPO DE SOPORTE |
|---|
| Nombre/término del tipo de soporte |
recurso electrónico |
| Código del tipo de soporte |
cr |
| Fuente |
rdacarrier |
| 347 ## - CARACTERÍSTICAS DEL ARCHIVO DIGITAL |
|---|
| Tipo de archivo |
text file |
| Formato de codificación |
PDF |
| 490 0# - MENCIÓN DE SERIE |
|---|
| Mención de serie |
UNIPA Springer Series |
| 500 ## - NOTA GENERAL |
|---|
| Nota general |
3.1 EPCs: A Real Hope or a Unrealizable Dream? |
| 500 ## - NOTA GENERAL |
|---|
| Nota general |
SpringerLink |
| 504 ## - NOTA DE BIBLIOGRAFÍA, ETC. |
|---|
| Nota de bibliografía, etc. |
Incluye referencias bibliográficas |
| 505 0# - NOTA DE CONTENIDO CON FORMATO |
|---|
| Nota de contenido con formato |
Preface; Acknowledgements; Contents; About the Author; Acronyms; 1 From Regenerative Medicine to Endothelial Progenitor Cells as Potential Candidates; Abstract; 1.1 Regenerative Medicine: A New Branch of Translational Medicine; 1.1.1 Stem Cell Therapy; 1.1.2 Stem Cells as Appropriate Candidates of Cell Therapy: Types of Stem Cell; 1.2 Endothelial Progenitor Cells: Other Emerging Candidates for RegMed Therapeutic Treatment; 1.2.1 Evidence of Several Circulating Subpopulations of EPCs; 1.2.2 EPCs: from BM progenitors to mature EC cells. |
| 505 8# - NOTA DE CONTENIDO CON FORMATO |
|---|
| Nota de contenido con formato |
1.3 Phenotypic Markers and Levels of Circulating EPCs in Adult Subjects1.3.1 EPC Quantification Using Flow Cytometry and Its Limitation; 1.3.2 Factors Modulating EPC Quantitative and Qualitative Evaluation by Flow Cytometry; 1.3.3 Pathological or Physiological Conditions as Factors Able to Modulate EPC Quantitative and Qualitative Evaluation; 1.4 The Complex Process of Regulation of EPC Biology and Function: New Insights on the Key Role of Notch, ROS and Wnt Pathways and Their Crosstalk, and Epigenetics; 1.5 Conclusions; Acknowledgements; References. |
| 505 8# - NOTA DE CONTENIDO CON FORMATO |
|---|
| Nota de contenido con formato |
2 Endothelial Progenitor Cells and Their Clinical Applications as Potential Disease Biomarkers and Therapeutic Agents: Evidence and Controversies Regarding Their EffectivenessAbstract; 2.1 Endothelial Dysfunction as the Early Event of Chronic Age-Related Diseases: EPCs as Cellular Biomarkers; 2.2 Relationship Between Circulating EPC Levels and Age-Related Diseases; 2.2.1 Unfavorable Factors Associated with Decreased Circulating EPC Levels; 2.2.2 Physiological Factors and High Circulating EPC Levels; 2.2.3 Exogenous Measures as Potential Strategies for Increasing Circulating EPC Levels. |
| 505 8# - NOTA DE CONTENIDO CON FORMATO |
|---|
| Nota de contenido con formato |
2.3 Correlation Between Blood EPC Levels and Cardiovascular Profile2.3.1 Atherosclerosis; 2.3.2 Hypertension; 2.3.3 Coronary Artery Disease (CAD); 2.3.4 Bicuspid Aortic Valve, Aortic Valve Regurgitation (AR) and Aneurysm; 2.3.5 Cerebral Ischemia; 2.3.6 Other CVD Diseases; 2.4 EPCs in Alzheimer Disease; 2.5 Diabetes and EPCs; 2.6 EPCs in Solid and Hematological Cancers, and Recent Controversies Relating to Their Incorporation into Tumor Neovessels; 2.7 EPCs as Therapeutic Agents; 2.7.1 EPCs as Therapeutic Agents for CVDs: Focus on Ischemic Disease Treatment, Capacity and Doubts. |
| 505 8# - NOTA DE CONTENIDO CON FORMATO |
|---|
| Nota de contenido con formato |
2.7.2 The Clinical Results and Indications of Autologous Therapies2.8 EPCs as Therapeutic Agents for Cancer: Focus on Anti-VEGF Treatments and Controversies in Their Efficacy; 2.9 EPCs as Therapeutic Agents for Alzheimer's Disease; 2.10 EPCs as Therapeutic Agents for Diabetes; 2.11 Controversies About EPC Use as Optimal Candidates for Cell Therapy; 2.12 Conclusions and Perspectives; References; 3 Endothelial Progenitor Cells: A Real Hope or an Unrealizable Dream? Which Measures or Strategies Are Necessary for making EPCs a clinical reality? Focus on a Potential Roadmap; Abstract. |
| 520 3# - SUMARIO, ETC. |
|---|
| Sumario, etc. |
This book explores the role of endothelial progenitor cells (EPCs) in the context of regenerative medicine (RegMed). In particular, it reveals the value of RegMed as a new TM branch intended to improve the health and quality of life, by restoring, maintaining or enhancing tissue and functions of organs. The book is divided into three chapters, the first of which describes the relevance of translational medicine (TM) as a new research approach to counteract the imposing challengeof age-related diseases. Of the diverse RegMed approaches, particular attention is paid to stem/progenitor cell-based therapies, their benefits and shortcomings, as well as to the description of types of stem and progenitor cells considered for regenerative cell therapies, such as EPCs as emerging candidates for RegMed applications. In turn, the second chapter outlines the clinical relevance of EPCs as both potential predictors, diagnostic and prognostic biomarkers of age-related diseases and therapeutic agents,discussing their advantages, disadvantages, and conflicting data. Chapter three proposes a potential roadmap for revising the findings and creating a clearer picture of valid data, which can provide support for various important aspects, i.e.isolating and characterizing EPCs by establishing standardized criteria for EPC research, identifying appropriate sub-populations for cell therapy, timing, dosing, priming of cells,and defining delivery modes for different applications. The book concludes with an overview of innovative strategies that could improve the efficacy of cell therapy at all levels, including cell priming, bio-nanotechnology, and tissue engineering. |
| 988 ## - NOTA LOCAL 598 |
|---|
| Nota local 598 (boletines) |
EBOOK, asignarmaterias, EBSPRINGER_2017D |
| 650 #7 - PUNTO DE ACCESO ADICIONAL DE MATERIA--TÉRMINO DE MATERIA |
|---|
| Término de materia o nombre geográfico como elemento de entrada |
Células madre |
| Fuente del encabezamiento o término |
embne |
| 9 (RLIN) |
160528 |
| 856 40 - LOCALIZACIÓN Y ACCESO ELECTRÓNICOS |
|---|
| Identificador Uniforme del Recurso |
https://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-55107-4 |
| Nota pública |
Acceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 999 ## - NÚMEROS DE CONTROL DE SISTEMA (KOHA) |
|---|
| -- |
1 |
| 942 ## - ELEMENTOS DE PUNTO DE ACCESO ADICIONAL (KOHA) |
|---|
| Fuente del sistema de clasificación o colocación |
Library of Congress Classification |
| Tipo de ítem Koha |
LIBRO-E NO PRÉSTAMO |
| 998 ## - DATOS ESTADÍSTICOS |
|---|
| Fecha de catalogación |
02/2018 |
| Tipo de materia |
E-book |
| Catalogador |
|
| Catalogado |
Sí |